Compare Recursion Pharmaceuticals Inc (RXRX) vs Suncor Energy Inc. (SU) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Recursion Pharmaceuticals Inc vs Suncor Energy Inc. — how do they compare? Recursion Pharmaceuticals Inc trades at $3.22 (market cap $1.74B), while Suncor Energy Inc. trades at $69.6 (market cap $80.89B). The key difference: Suncor Energy Inc. is far larger — about 46.5× Recursion Pharmaceuticals Inc's market cap, and Suncor Energy Inc. pays a 2.51% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals.
| RXRX | SU | |
|---|---|---|
Market Cap | $1.74B | $80.89B |
Sector | Health | Energy |
52-Week High | $6.79 | $69.73 |
52-Week Low | $2.84 | $38.17 |
Enterprise Value | $1.26B | $87.64B |
Dividend Yield | — | 2.51% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
RXRX trades at $3.44, down 5.23% today, with a bullish technical signal from moving averages but neutral oscillators. The company reported Q2 2026 earnings miss with revenue of $54M and net loss of -$519M, though it maintains partnerships with Genentech and Sanofi. Analyst consensus shows 40% buy ratings with institutional interest from CalSTRS increasing its stake by 64% in Q2 2026.
Outlook remains speculative with significant losses (-961.97% net margin) offset by AI-driven drug discovery potential. Key risks include cash burn and pipeline delays, while catalysts involve clinical progress. The stock offers high-risk growth exposure in TechBio, dependent on platform validation and partnership milestones.
Suncor Energy (SU) trades at $67.89, up 0.83% with a bullish technical outlook. The stock shows strong fundamentals with a P/E of 12.54, net margin of 14.7%, and robust cash flow generation. Recent Q2 2026 earnings beat expectations at $2.27 EPS versus $2.14 expected. Analyst consensus is overwhelmingly positive with 74% buy ratings. The company maintains solid balance sheet metrics with debt-to-asset ratio improving to 11.1% in 2025.
SU presents a compelling value opportunity with attractive valuation multiples and strong profitability. Near-term catalysts include leadership transition with Peter Zebedee becoming CEO in 2027 and continued shareholder returns via dividends and buybacks. Key risks include commodity price volatility and operational challenges from weather disruptions. The stock's current technical setup supports further upside potential toward resistance at $69-71.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →About Suncor Energy Inc.
Suncor Energy Inc is an integrated energy company. The company's operations include oil sands development, production and upgrading, offshore oil and gas, petroleum refining in Canada and the U.S. and the company's PetroCanada retail and wholesale distribution networks. The company is developing petroleum resources while advancing the transition to a low-emissions future through investment in power, renewable fuels and hydrogen. It also conducts energy trading activities focused principally on the marketing and trading of crude oil, natural gas, byproducts, refined products and power.
Read more on SU →
